Management of Rising WBC Count in Suspected Polycythemia Vera

Diagnostic Evaluation

The American Society of Hematology recommends confirming JAK2 mutation status, obtaining peripheral blood smear, measuring serum erythropoietin levels, checking complete metabolic panel and uric acid, and assessing iron studies in patients with suspected polycythemia vera 2
The European Hematology Association suggests that more than 95% of PV patients harbor JAK2 mutations, which distinguishes primary from secondary erythrocytosis 2

The National Comprehensive Cancer Network recommends assessing thrombotic risk in patients with polycythemia vera, as elevated WBC count is independently associated with increased thrombotic events 1
The American College of Cardiology suggests that patients with WBC count ≥11.0 × 10⁹/L are at higher risk for thrombotic events 3

The American Society of Hematology recommends initiating low-dose aspirin (81-100 mg daily) immediately in patients with polycythemia vera, unless contraindications exist 1
The European Hematology Association suggests that hydroxyurea is the first-line cytoreductive agent at any age, though use in patients <40 years requires careful consideration due to potential leukemogenic risk 3
The National Comprehensive Cancer Network recommends determining if patients meet high-risk criteria requiring cytoreductive therapy, including age ≥60 years, prior thrombotic event, progressive leukocytosis, symptomatic or progressive splenomegaly, and severe disease-related symptoms 1, 3

The American College of Cardiology recommends monitoring complete blood count (CBC) weekly until WBC count stabilizes <10 × 10⁹/L, and then monthly once stable on therapy 2, 5
The European Hematology Association suggests that target parameters for complete response criteria include hematocrit <45% without phlebotomy, platelet count <400 × 10⁹/L, WBC count <10 × 10⁹/L, and no disease-related symptoms 3, 1

The National Comprehensive Cancer Network recommends considering cytoreductive therapy in patients with WBC count ≥10 × 10⁹/L, even if other high-risk features are absent, as this represents uncontrolled myeloproliferation 3, 1
The American Society of Hematology suggests that interferon-alfa or pegylated interferon is preferred in younger patients (<40 years) and is non-leukemogenic 3, 1